Correlation Between BioLineRx and Seres Therapeutics
Can any of the company-specific risk be diversified away by investing in both BioLineRx and Seres Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioLineRx and Seres Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BioLineRx and Seres Therapeutics, you can compare the effects of market volatilities on BioLineRx and Seres Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioLineRx with a short position of Seres Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioLineRx and Seres Therapeutics.
Diversification Opportunities for BioLineRx and Seres Therapeutics
0.69 | Correlation Coefficient |
Poor diversification
The 3 months correlation between BioLineRx and Seres is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding BioLineRx and Seres Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Seres Therapeutics and BioLineRx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BioLineRx are associated (or correlated) with Seres Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Seres Therapeutics has no effect on the direction of BioLineRx i.e., BioLineRx and Seres Therapeutics go up and down completely randomly.
Pair Corralation between BioLineRx and Seres Therapeutics
Given the investment horizon of 90 days BioLineRx is expected to under-perform the Seres Therapeutics. In addition to that, BioLineRx is 1.58 times more volatile than Seres Therapeutics. It trades about -0.16 of its total potential returns per unit of risk. Seres Therapeutics is currently generating about -0.02 per unit of volatility. If you would invest 83.00 in Seres Therapeutics on December 29, 2024 and sell it today you would lose (11.00) from holding Seres Therapeutics or give up 13.25% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
BioLineRx vs. Seres Therapeutics
Performance |
Timeline |
BioLineRx |
Seres Therapeutics |
BioLineRx and Seres Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with BioLineRx and Seres Therapeutics
The main advantage of trading using opposite BioLineRx and Seres Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioLineRx position performs unexpectedly, Seres Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will offset losses from the drop in Seres Therapeutics' long position.BioLineRx vs. Ardelyx | BioLineRx vs. Lexicon Pharmaceuticals | BioLineRx vs. Seres Therapeutics | BioLineRx vs. Immunitybio |
Seres Therapeutics vs. Syros Pharmaceuticals | Seres Therapeutics vs. Iovance Biotherapeutics | Seres Therapeutics vs. Veracyte | Seres Therapeutics vs. Fate Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Complementary Tools
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |